We provide seamless transition from laboratory-scale discovery to pilot and large-scale industrial production. Our integrated workflow ensures consistent biological activity and target purity throughout every stage of your scale-up process.
Next-IO™ Tumor Associated Antigens
Creative Biolabs offers a specialized suite of laboratory services dedicated to the rigorous identification and detailed characterization of novel tumor targets. We provide oncology researchers with a streamlined transition from initial high-throughput antigen screening to industrial-scale production of high-purity biological materials. By partnering with our team, clients gain access to exclusive targets validated for stability in hostile environments and screened for immune-evasion risks. Our core mission is to supply the data-rich biological materials and datasets necessary to drive next-generation research leads toward success.
Introduction What We Can Offer How We Can Help Why Choose Us Customer Reviews FAQs Related Services Contact Us
Scientific Background of Next-IO™ Tumor Associated Antigens
Tumor Associated Antigens (TAAs), particularly Cancer-Germline antigens, represent a gold standard for targeted oncology research because of their restricted expression and high immunogenicity. Established scientific literature confirms that factors such as thymic imprinting and metabolic stress within the tumor microenvironment are primary drivers of research failures in modern drug discovery. Creative Biolabs integrates these critical findings, utilizing advanced epigenetic re-awakening and metabolic validation protocols to ensure that targets are not only present but functionally accessible, providing a robust foundation for next-generation research breakthroughs.
Request a Consultation →
Fig.1 Classification of tumor antigens. 1
What We Can Offer
One-stop fermentation and synthesis service
Strict aseptic verification and certified production
Our production lines adhere to the highest quality standards for downstream research applications. We implement rigorous aseptic protocols and environmental monitoring to prevent contamination and ensure product consistency.
Advanced Quality-by-Design (QbD) and PAT systems
We utilize sophisticated process analytical technologies to monitor and control production in real-time. This ensures the stability of antigen clones and maintains high-performance standards in cell banks and large-scale bioreactors.
Fully customizable project scopes
Our flexible service allows for tailored epitope mapping, specific PTM engineering, and various delivery formats. Whether you require mRNA, recombinant proteins, or viral vectors, we adapt to your research goals.
How Creative Biolabs Can Assist Your Project
At Creative Biolabs, we recognize that oncology researchers require more than just a sequence; they require a partner capable of moving from laboratory discovery to industrial-scale material supply without compromising target integrity. We provide a customized, one-stop service for Next-IO™ Tumor Associated Antigens tailored to your specific research modality.
Bispecific →
CD47 × PD-L1 Anti-BCMA × CD3 Anti-CD123 × CD3 CD47 × CD19 CD47 × MSLN Anti-GPC3 × CD3 Anti-GPRC5D × CD3 Anti-MUC16 × CD3 Anti-PSMA × CD3 Anti-SSTR2 × CD3 Anti-MSLN × CD3 Anti-CD47 × PD-L1 Anti-CD47 × CD20 Anti-PD-L1 × 4-1BB PD-L1 x TIM-3 PD-1 x CTLA-4 PSCA x CD3 4-1BB × PD-L1 c-MET x CTLA-4 CTLA-4 x OX40 GITR x CTLA-4 HER2 x HER3 LAG-3 × PD-L1 LAG-3 x CTLA-4
Others →
CD47 × PD-L1 Dual-Targeted Fusion Protein CD47 × EGFR Dual-Targeted Fusion Protein TGF-β × PD-L1 Bi-Functional Fusion Protein Anti-GPA33 × CD3 Bispecific DART Protein Anti-GPC3 CAR-T Cell Anti-GPC3 CAR-NK Cell Anti-CDH3 × CD3 Bispecific DART Protein Anti-MSLN Fusion Protein Anti-PD-L1 × 4-1BB Bispecific DART Anti-GPC3 Vaccine CD22 × CD19 CAR-T CD22 CAR-T
Highlights
Prioritizing Biological Quality
Creative Biolabs leads the field by moving beyond simple antigen presence to ensure superior biological quality. We focus on the functional integrity of every target to enhance your downstream research outcomes.
Overcoming Immune Tolerance
Our unique platform integrates fetal imprinting analysis to ensure your candidates bypass central tolerance. This specialized screening ensures that your leads remain effective where others often fail in research models.
Ensuring Metabolic Resilience
We validate every antigen against metabolic stress and hypoxia to simulate realistic conditions. This ensures that your therapeutic candidates maintain visibility and performance within the challenging, immunosuppressive tumor microenvironment.
Minimized Off-Target Risks
Our targets are strategically sequestered by the Blood-Testis Barrier for maximum safety. This unique biological localization offers a reduced risk profile for off-target binding in healthy, non-malignant tissue types.
Connect with our experts today to receive a comprehensive technical quote tailored to your specific project parameters and discovery milestones.
Customer Reviews
-
Bypassing Immune Tolerance
Creative Biolabs' screening service allowed our team to identify highly active targets that were previously overlooked. We achieved a notable increase in immune response within our models, significantly accelerating our early-stage discovery timeline. - S**h. J. -
Exceptional TME Stability
The targets provided remained visible and stable even under extreme laboratory conditions mimicking tumor stress. This reliability allowed us to develop more robust molecular candidates that maintain performance where others typically fail. - Prof. R**t. K.
FAQs
How does the Thymic Filter Simulation assist in research?
It identifies antigens expressed in the fetal thymus which often trigger low-avidity immune responses. By selecting un-imprinted candidates, we ensure your research leads can trigger potent, high-affinity reactions in experimental oncology models.
Can these antigens be used for "off-the-shelf" research products?
Yes, our TAAs are strategically chosen for their high prevalence across broad tumor populations. This high frequency makes them ideal foundations for the development of standardized, off-the-shelf molecular tools and assays.
Related Services
Antibody Humanization Service
We provide advanced CDR-grafting and structure-based optimization to convert non-human antibodies into human-compatible leads, ensuring minimal immunogenicity and maintained binding affinity for clinical translational research.
Learn More →Humanized Models
We provide sophisticated mouse models reconstructed with human immune systems to evaluate TAA-targeted therapies, offering a high-fidelity environment for testing efficacy and safety before entering clinical trials.
Learn More →How to Contact Us
To access our detailed data packages, review custom validation protocols, or to discuss the specific technical requirements of your research program, our senior scientists are ready to assist. We offer personalized consultations to ensure our platform aligns perfectly with your experimental goals, providing the specialized expertise necessary to overcome the unique challenges of your target discovery project.
Contact our team for detailed data packages and to discuss your strategic project milestones.
Reference
- Feola, Sara et al. "Uncovering the Tumor Antigen Landscape: What to Know about the Discovery Process." Cancers vol. 12,6 1660. 23 Jun. 2020. Distributed under an Open Access license CC BY 4.0, without modification. https://doi.org/10.3390/cancers12061660
Download our brochureLoading case studies...
Online Inquiry